Biosimilars and Non-Innovator Biologics in Emerging Markets: Payer, Regulator and Pharma Strategies
The market for biosimilars and non-innovator biologics is growing exponentially. Emerging markets offer one of the best opportunities for growth and expansion, however, these markets are not without risk, as the landscapes for market access, pricing and product lifecycle remain uncertain. Developing smart strategies will be the key to success for biosimilars and originator biologics in these pivotal markets.
Following our ground-breaking multi-client studies on biosimilars in 2007-2009, IHS is pleased to present Biosimilars and Non-Innovator Biologics in Emerging Markets: Payer, Regulator and Pharma Strategies. Our previous research focused on the emerging pathways for these drugs in developed markets, and this study now provides an in-depth analysis of the regulatory and pricing and reimbursement landscapes for biosimilars and non-innovator biologics in emerging markets.
Answering your key questions
- Who are the regulatory decision makers, and what guidelines do they follow?
- What are the regulatory evidence requirements in each country?
- What does the reimbursement landscape look like across countries?
- What price differential do payers expect between originator biologics and biosimilars in each market?